Clinical Scorecard: Understanding Myopia Management Options: Atropine
At a Glance
| Category | Detail |
|---|---|
| Condition | Myopia |
| Key Mechanisms | Atropine drop therapy for myopia control |
| Target Population | Children with myopia |
| Care Setting | Optometry practices |
Key Highlights
- Atropine has been used for myopia control for decades.
- Low-dose atropine (0.01% to 0.05%) shows efficacy with minimal side effects.
- Dosing is once nightly, with adjustments based on patient response.
- No FDA-approved low-dose atropine drops are available in the U.S.
- Compounding is necessary for low-dose formulations.
Guideline-Based Recommendations
Diagnosis
- Assess myopia severity and progression in children.
Management
- Consider low-dose atropine (0.05% preferred) for myopia control.
Monitoring & Follow-up
- Monitor children for visual discomfort during the day.
Risks
- Potential side effects include near blur and glare.
Patient & Prescribing Data
Children experiencing myopia progression.
Dosage should be patient-driven and can be adjusted based on side effects.
Clinical Best Practices
- Start with 0.05% atropine for initial treatment.
- Educate parents about potential side effects.
- Ensure proper compounding of atropine drops.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.